- Archer Materials (AXE) develops sensing pathways to detect genetic information through its biochip technology
- The company’s technology is being developed to detect diseases through analysis of biological specimen droplets using graphene-based sensor devices
- The reactions developed have the potential for on-chip detection and quantification of specific DNA or RNA fragments relevant to viruses and bacteria
- Archer’s CEO Dr Mohammad Choucair says this provides the biochemical foundations to potentially allow for future operations and applications of the biochip
- Shares have been trading 7.3 per cent higher at $1.32
Archer Materials (AXE) has developed sensing pathways to detect genetic information through its biochip technology.
The company is developing its biochip which aims to detect diseases through analysis of biological specimen droplets using graphene-based sensor devices integrated in on-chip devices.
Last month, Archer announced it had fabricated, on silicon wafers, nano-sized biochip components inside hair-thin microfluidic channels required for the processing, mixing and transportation of biological specimens.
Now, it has developed its first biochemical reactions for the detection and quantification of nucleic acid sequences, both DNA and RNA, for potential use and application at room temperature in its biochip technology.
According to the company’s CEO, Dr Mohammad Choucair, this development provides the biochemical foundations to potentially allow for future operations and applications of Archer’s biochip in the detection of various diseases.
“There are few examples of lab-on-a-chip technologies that detect nucleic acids without the need for PCR,” he said.
“Archer’s biochemical processes could potentially allow for on-chip detection of pathogens, with several practical advantages, including eliminating cold-logistics supply chain requirements and the need for PCR, if favourable.”
Shares were trading 7.35 per cent higher at $1.32 at 2:06 pm AEDT.